Klivira
Request demo

Streamlining Blue Shield of California Aimovig Prior Authorization

Navigating the Blue Shield of California Aimovig prior authorization process efficiently is critical for patient access to this preventive migraine therapy.

For revenue cycle directors and prior authorization coordinators, understanding the specific requirements for Aimovig (erenumab) under Blue Shield of California (BSCA) is paramount. This guide provides a clear overview of the channels, policies, and regulatory considerations to optimize prior authorization workflows and minimize denials.

Understanding Aimovig (Erenumab) for Prior Authorization

Aimovig, also known by its generic name erenumab, is a CGRP receptor antagonist indicated for the preventive treatment of chronic and episodic migraine. As a specialty medication, its authorization often involves specific clinical criteria and may be subject to step therapy requirements, typically through generic preventive migraine therapies, before approval.

Blue Shield of California Prior Authorization Channels for Aimovig

Blue Shield of California processes prior authorizations for Aimovig based on whether it falls under the medical or pharmacy benefit. Medical-benefit submissions, common for provider-administered specialty drugs, are routed through the Blue Shield Provider Connection portal at blueshieldca.com or via X12 278 transactions through clearinghouses. For pharmacy-benefit Aimovig, the specific PBM relationship governing Blue Shield of California's plans requires verification, as PBMs can vary nationally across Blue Cross Blue Shield plans.

Navigating Blue Shield of California's Utilization Management Policies

Blue Shield of California publishes its medical policy and clinical utilization management guideline libraries on its provider site. These resources outline the specific clinical criteria for Aimovig coverage, including diagnostic requirements, contraindications, and prior treatment failures. BSCA policies specify whether criteria are internally developed, based on MCG, or other external sources, which is crucial for preparing a robust prior authorization submission.

California-Specific Regulatory Considerations for Aimovig PA

Prior authorization turnaround times and processes for Blue Shield of California plans are influenced by California state insurance regulations. HMO plans fall under the California Department of Managed Health Care (DMHC), while PPO plans are regulated by the California Department of Insurance (CDI). Additionally, Blue Shield of California's Medicare Advantage, Medi-Cal managed care, and Covered California plans are impacted by federal CMS-0057-F phased prior authorization timeframes and specific state mandates.

Common Denial Reasons and Appeal Pathways with Blue Shield of California

Denials for Aimovig prior authorizations by Blue Shield of California typically align with standard X12 277/835 denial codes and portal status messages. Common reasons include insufficient clinical documentation to meet medical necessity criteria, failure to complete step therapy, or issues with member eligibility. If a prior authorization is denied, providers can initiate an internal appeal through BSCA's documented appeal pathway. For unresolved denials, California offers external review options via the DMHC's Independent Medical Review (IMR) program for HMO plans or a separate process for CDI-regulated PPO plans. Medicare Advantage denials follow the CMS 5-level appeal structure.

Frequently asked questions

What is Aimovig (erenumab) used for?

Aimovig (erenumab) is a CGRP receptor antagonist primarily used for the preventive treatment of both chronic and episodic migraine in adults. It is administered via subcutaneous injection.

How do I submit an Aimovig prior authorization to Blue Shield of California?

Submissions for medical-benefit Aimovig can be made through the Blue Shield Provider Connection portal at blueshieldca.com or via X12 278 electronic transactions. For pharmacy-benefit Aimovig, the submission channel depends on Blue Shield of California's specific PBM partner, which should be verified.

Where can I find Blue Shield of California's medical policies for Aimovig?

Blue Shield of California publishes its medical policies and clinical utilization management guidelines, including those relevant to Aimovig, on its provider website at blueshieldca.com. Accessing these resources is essential for understanding the specific clinical criteria required for approval.

What are the typical PA turnaround times for Aimovig with Blue Shield of California?

Prior authorization turnaround times for Blue Shield of California are governed by California state regulations (DMHC for HMOs, CDI for PPOs), which differ from federal standards. For Medicare Advantage, Medi-Cal managed care, and Covered California plans, federal CMS-0057-F timeframes also apply, alongside specific state mandates.

What are common reasons for Aimovig PA denials by Blue Shield of California?

Common denial reasons include insufficient clinical documentation to demonstrate medical necessity, failure to meet step therapy requirements (e.g., trying and failing generic preventive therapies), or issues with member eligibility or plan coverage. Understanding BSCA's specific policy criteria is key to avoiding these denials.

How do I appeal an Aimovig prior authorization denial from Blue Shield of California?

You can initiate an internal appeal by following the process outlined in Blue Shield of California's provider manual. If the internal appeal is unsuccessful, California offers external review options: the DMHC's Independent Medical Review (IMR) for HMO plans, or a separate external review process for CDI-regulated PPO plans. Medicare Advantage denials follow the CMS 5-level appeal structure.

Related coverage

Other aimovig prior authorization by payer

Other aimovig prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo